CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced additional positive efficacy data on AP23573 – its novel mTOR inhibitor – from further analysis of its ongoing Phase 2 trial of AP23573 in patients with metastatic and/or unresectable soft-tissue and bone sarcomas. The expanded analysis focuses on the 60 patients with an AP23573 clinical-benefit response (CBR) – the primary endpoint of the 212-patient trial – and its relationship to overall survival. The new results demonstrate that documented disease stabilization and/or tumor regression with single-agent AP23573 is a strong predictor of improved overall survival.
